HFA
PRTK

Hoover Financial Advisors’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Hoover Financial Advisors’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$1K Hold
200
– – ﹤0.01% 635
2021
Q1 		$1K Hold
200
– – ﹤0.01% 590
2020
Q4 		$1K Buy
+200
New +$1.18K ﹤0.01% 520
2020
Q3 		– Sell
-200
Closed -$1K – 502
2020
Q2 		$1K Buy
+200
New +$888 ﹤0.01% 488

Other funds holding PRTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hoover Financial Advisors's PRTK Position: Q2 2021 in Review

Hoover Financial Advisors held its Paratek Pharmaceuticals, Inc. (PRTK) position steady in Q2 2021 at 200 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #635.

Hoover Financial Advisors first reported a position in PRTK in Q2 2020 and has held it in 4 quarters since. 116 funds tracked by Wall St. Rank hold PRTK as of Q2 2021.

  • Hoover Financial Advisors held 200 shares of Paratek Pharmaceuticals, Inc. worth $1K as of Q2 2021.
  • Hoover Financial Advisors left its Paratek Pharmaceuticals, Inc. share count unchanged in Q2 2021.
  • Paratek Pharmaceuticals, Inc. made up ﹤0.01% of Hoover Financial Advisors's portfolio in Q2 2021, its #635 holding.
  • Hoover Financial Advisors first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2020 and has held it in 4 quarters since.
  • 116 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2021.

Based on Hoover Financial Advisors's 13F filing for Q2 2021, filed 28 Jul 2021.